Skip to main content

Table 2 Efficacy in the intention-to-treat population

From: Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRASmetastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Variable ITT population N = 99
Response, n (%)  
  Complete response 4 (4.0)
  Partial response 56 (56.6)
  Stable disease 30 (30.3)
  Progressive disease 5 (5.1)
  Not available 4 (4.0)
ORR, % (95% CI) 60.6 (50.3 to 70.3)
DCR, % (95% CI) 90.9 (83.4 to 95.8)
Progression-free survival  
  Progression event, n (%) 68 (68.7)
  Months of progression-free survival, median (Q1-Q3) 10.1 (6.5-14.8)
Overall survival  
  Death, n (%) 57 (57.6)
  Months of overall survival, median (Q1-Q3) 20.8 (11.6-32.8)
  1. Abbreviations: CI confidence interval, DCR disease control rate, ITT intention-to-treat, ORR objective response rate, Q1-Q3 Interquarile range.